GlassScriptPhysician profile
Mary Carmon
NPI 1558781534
$6,170.58
in general payments reported to CMS, 2019-2025
25 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $289 · 2022: $1,267 · 2023: $1,254 · 2024: $1,873 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,424 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,423.71 |
| Education | $191.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,454.73 | 2021-2025 | |
| Janssen Biotech, INC. | $724.89 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $669.62 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $613.70 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $558.80 | 2021-2025 | |
| Ucb, INC. | $396.25 | 2022-2025 | Bimzelx |
| Amgen INC. | $383.91 | 2022-2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $257.03 | 2022-2025 | Sotyktu |
| Organogenesis INC. | $243.50 | 2021-2025 | Cygnus Dual, Apligraf, Novachor |
| Lilly USA, LLC | $136.44 | 2021-2024 | Ebglyss, Taltz |
| Sun Pharmaceutical Industries INC. | $136.20 | 2021-2025 | |
| Galderma Laboratories, L.P. | $114.78 | 2024-2025 | Nemluvio |
| Leo Pharma INC. | $113.77 | 2023-2025 | Adbry, Anzupgo |
| Convatec INC. | $49.43 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $44.80 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $43.11 | 2023 | Ameluz, Bf-Rhodoled, Xepi |
| Incyte Corporation | $38.82 | 2022-2024 | Opzelura |
| Pfizer INC. | $36.44 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.21 | 2022-2025 | Spevigo |
| Genentech USA, INC. | $35.41 | 2023-2024 | Erivedge |
| Allergan, INC. | $21.58 | 2022 | |
| Fresenius Kabi USA, LLC | $17.49 | 2024 | Idacio |
| Journey Medical Corporation | $15.84 | 2023 | |
| Arcutis Biotherapeutics, INC. | $15.11 | 2024 | Zoryve |
| Bioventus LLC | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Carmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.